E-Mail
PITTSBURGH, 26 January 2021 - A vaginal ring containing the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel delivered sustained levels of each drug when used continuously for 90 days - levels likely sufficient to serve its dual purpose for protecting against both HIV and unwanted pregnancy, according to findings of a new study.
Results of the Phase I study of the 90-day dual-purpose ring are being presented at the HIV Research for Prevention (HIVR4P) Virtual Conference, or HIVR4P // Virtual, which is taking place over the course of four days: Jan. 27-28 and Feb. 3-4.
The study, MTN-044/IPM 053/CCN019, was conducted by researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) in collaboration with NIH s Contraceptive Clinical Trials Network (CCTN) and is the first to evaluate the ring s use, as intended, for 90 days. In an earlier first-in-human study (MTN-030/IPM 041), also conducted by the MTN, women use
Covid-19 Stigma – Guilt and Shame Will Not Work
January 25, 2021
When Charles Bungu, a 40-year old banker (not real name) tested positive for Covid-19, he immediately went into self-isolation as he had mild symptoms.
His absence from work after everyone at their branch had been tested was confirmation to his workers that he had tested positive for Covid-19.
Day in, day out, some of his workmates checked on him through calls and Whatsapp messages, with others wanting to know more about his condition, how he felt, if he thought he had infected anyone at work, among other issues.
Others wanted to know where he got infected.
Wednesday, 27 January 2021, 7:57 am
Results of the Antibody Mediated Prevention (AMP) studies
to be presented at the IAS HIV Research for Prevention
(HIVR4P // Virtual) conference.
Tuesday, 26
January, 2021 (Geneva, Switzerland) IAS – the
International AIDS Society – welcomes new results from two
proof-of-concept studies (HVTN 704/HPTN 085 and HVTN
703/HPTN 081- the AMP Studies) demonstrating that infusions
of the broadly neutralizing monoclonal HIV antibody (bNAb)
VRC01 can prevent some HIV infections.
The AMP results include
data from more than 4,600 participants in two studies that
enrolled HIV-negative men and transgender people who have
sex with men in the U.S., Brazil and Peru (HVTN 704/HPTN
For the first time, researchers say infusions of antibodies can prevent HIV infection Source:
Corey L, et al. Abstract 1480. Presented at: HIV Research for Prevention; Jan. 27-28 and Feb. 3-4, 2021 (virtual meeting). Disclosures: Fauci reports no relevant financial disclosures. Healio could not confirm financial disclosures for Corey or Mgodi at the time of publishing. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS
You ve successfully added to your alerts. You will receive an email when new content is published.
The message from all scientists is very loud and clear that vaccines alone will not be able to stem the tide of the COVID-19 pandemic. Even after getting vaccinated, we will have to continue to wear masks, maintain physical distancing, wash hands .